Starboard refrains from nominating directors to Pfizer's board - Bloomberg

Published 27/01/2025, 17:58
© Reuters

Investing.com -- Pfizer Inc. (NYSE:PFE) has temporarily avoided a standoff with activist investor Starboard Value LP. According to Bloomberg sources, Starboard did not put forward any nominations for Pfizer's board before the January 25 deadline for the pharmaceutical company's annual meeting in April.

This development takes some strain off Pfizer's CEO, Albert Bourla, who has maintained that the company is set to recover from its sharp downturn after the pandemic. Pfizer, a drug manufacturer based in New York, has seen its shares drop more than 50% since 2021. This decline is attributed to the reduced demand for its Covid-related drugs and a number of high-priced acquisitions, which have raised doubts among investors.

This situation may not be entirely resolved. Starboard, which invested roughly $1 billion in Pfizer towards the end of last year, might still propose alterations to Pfizer's board in 2026, provided the two parties do not come to an agreement beforehand.

Starboard's CEO, Jeff Smith, has previously criticized Pfizer's management for causing a loss of at least $20 billion in market value. He attributed this to ill-advised acquisitions and investments in an uninspiring drug pipeline. Smith suggested in October that replacing Bourla "could make sense."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.